company background image
ITCI

Intra-Cellular TherapiesNasdaqGS:ITCI Stock Report

Market Cap

US$3.1b

7D

-11.3%

1Y

55.3%

Updated

02 Dec, 2021

Data

Company Financials +
ITCI fundamental analysis
Snowflake Score
Valuation2/6
Future Growth5/6
Past Performance0/6
Financial Health5/6
Dividends0/6

ITCI Stock Overview

Intra-Cellular Therapies, Inc., a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases, and other disorders of the central nervous system (CNS) in the United States.

Rewards

Trading at 91.8% below our estimate of its fair value

Earnings are forecast to grow 63.6% per year

Risk Analysis

No risks detected for ITCI from our risk checks.

Intra-Cellular Therapies Competitors

Pfizer

NYSE:PFE

US$306.9b

Eli Lilly

NYSE:LLY

US$225.9b

Teva Pharmaceutical Industries

NYSE:TEVA

US$9.0b

AstraZeneca

LSE:AZN

UK£128.8b

Price History & Performance

Summary of all time highs, changes and price drops for Intra-Cellular Therapies
Historical stock prices
Current Share PriceUS$38.62
52 Week HighUS$47.03
52 Week LowUS$24.36
Beta1.08
1 Month Change-17.55%
3 Month Change11.62%
1 Year Change55.29%
3 Year Change185.44%
5 Year Change141.83%
Change since IPO286.20%

Recent News & Updates

Nov 08

Intra-Cellular Therapies: A Leader In The Psychiatric Medicine Space

As a stellar neuroleptic, Caplyta demonstrated robust efficacy and an excellent safety profile. Intra-Cellular Therapies is expanding Caplyta's label for bipolar depression as well as other indications. As the December 17 PDUFA is approaching for Caplyta in bipolar depression, you can expect this stock to potentially move aggressively.

Aug 06
We're Hopeful That Intra-Cellular Therapies (NASDAQ:ITCI) Will Use Its Cash Wisely

We're Hopeful That Intra-Cellular Therapies (NASDAQ:ITCI) Will Use Its Cash Wisely

We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...

Shareholder Returns

ITCIUS PharmaceuticalsUS Market
7D-11.3%-2.7%-3.5%
1Y55.3%12.4%19.4%

Return vs Industry: ITCI exceeded the US Pharmaceuticals industry which returned 12.4% over the past year.

Return vs Market: ITCI exceeded the US Market which returned 19.4% over the past year.

Price Volatility

Is ITCI's price volatile compared to industry and market?
ITCI volatility
ITCI Average Weekly Movement5.9%
Pharmaceuticals Industry Average Movement9.3%
Market Average Movement6.1%
10% most volatile stocks in US Market14.9%
10% least volatile stocks in US Market2.4%

Stable Share Price: ITCI is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 6% a week.

Volatility Over Time: ITCI's weekly volatility (6%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
n/a383Sharon Mateshttps://www.intracellulartherapies.com

Intra-Cellular Therapies, Inc., a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases, and other disorders of the central nervous system (CNS) in the United States. The company offers CAPLYTA for the treatment of schizophrenia in adults. It is also developing lumateperone, which is in Phase 3 clinical trials for the treatment of bipolar depression, as well as to treat autism spectrum disorder, and sleep disorders associated with neuropsychiatric and neurological disorders.

Intra-Cellular Therapies Fundamentals Summary

How do Intra-Cellular Therapies's earnings and revenue compare to its market cap?
ITCI fundamental statistics
Market CapUS$3.14b
Earnings (TTM)-US$259.09m
Revenue (TTM)US$70.59m

44.6x

P/S Ratio

-12.1x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
ITCI income statement (TTM)
RevenueUS$70.59m
Cost of RevenueUS$80.32m
Gross Profit-US$9.74m
ExpensesUS$249.35m
Earnings-US$259.09m

Last Reported Earnings

Sep 30, 2021

Next Earnings Date

n/a

Earnings per share (EPS)-3.18
Gross Margin-13.79%
Net Profit Margin-367.06%
Debt/Equity Ratio0%

How did ITCI perform over the long term?

See historical performance and comparison

Valuation

Is Intra-Cellular Therapies undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: ITCI ($38.62) is trading below our estimate of fair value ($468.61)

Significantly Below Fair Value: ITCI is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: ITCI is unprofitable, so we can't compare its PE Ratio to the US Pharmaceuticals industry average.

PE vs Market: ITCI is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate ITCI's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: ITCI is overvalued based on its PB Ratio (6.5x) compared to the US Pharmaceuticals industry average (2.7x).


Future Growth

How is Intra-Cellular Therapies forecast to perform in the next 1 to 3 years based on estimates from 8 analysts?

63.6%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: ITCI is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2%).

Earnings vs Market: ITCI is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: ITCI's is expected to become profitable in the next 3 years.

Revenue vs Market: ITCI's revenue (53.2% per year) is forecast to grow faster than the US market (10% per year).

High Growth Revenue: ITCI's revenue (53.2% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: ITCI's Return on Equity is forecast to be low in 3 years time (4%).


Past Performance

How has Intra-Cellular Therapies performed over the past 5 years?

-18.9%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: ITCI is currently unprofitable.

Growing Profit Margin: ITCI is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: ITCI is unprofitable, and losses have increased over the past 5 years at a rate of 18.9% per year.

Accelerating Growth: Unable to compare ITCI's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: ITCI is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (12.2%).


Return on Equity

High ROE: ITCI has a negative Return on Equity (-53.23%), as it is currently unprofitable.


Financial Health

How is Intra-Cellular Therapies's financial position?


Financial Position Analysis

Short Term Liabilities: ITCI's short term assets ($533.2M) exceed its short term liabilities ($49.9M).

Long Term Liabilities: ITCI's short term assets ($533.2M) exceed its long term liabilities ($20.3M).


Debt to Equity History and Analysis

Debt Level: ITCI is debt free.

Reducing Debt: ITCI has no debt compared to 5 years ago when its debt to equity ratio was 31%.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: ITCI has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if ITCI has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.


Dividend

What is Intra-Cellular Therapies's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate ITCI's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate ITCI's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if ITCI's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if ITCI's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of ITCI's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

4.7yrs

Average management tenure


CEO

Sharon Mates (68 yo)

8.33yrs

Tenure

US$5,475,679

Compensation

Dr. Sharon Mates, Ph D., co-founded Intra-Cellular Therapies, Inc. (a/k/a ITI) in May 2002 and has been its Chairman, President and Chief Executive Officer since June 2002. Earlier in her career, Dr. Mates...


CEO Compensation Analysis

Compensation vs Market: Sharon's total compensation ($USD5.48M) is about average for companies of similar size in the US market ($USD5.28M).

Compensation vs Earnings: Sharon's compensation has increased whilst the company is unprofitable.


Leadership Team

Experienced Management: ITCI's management team is considered experienced (4.7 years average tenure).


Board Members

Experienced Board: ITCI's board of directors are considered experienced (8.3 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Intra-Cellular Therapies, Inc.'s employee growth, exchange listings and data sources


Key Information

  • Name: Intra-Cellular Therapies, Inc.
  • Ticker: ITCI
  • Exchange: NasdaqGS
  • Founded: NaN
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$3.140b
  • Shares outstanding: 81.46m
  • Website: https://www.intracellulartherapies.com

Number of Employees


Location

  • Intra-Cellular Therapies, Inc.
  • 430 East 29th Street
  • Suite 900
  • New York
  • New York
  • 10016
  • United States

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/12/02 23:39
End of Day Share Price2021/12/02 00:00
Earnings2021/09/30
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.